S&P MidCap 400 Pure Growth Fund HALO Holdings History
S&P MidCap 400 Pure Growth Fund's Halozyme Therapeutics Inc Holding Summary
As of 2025-03-31, RYDEX SERIES FUNDS held 6,559.00 shares of Halozyme Therapeutics Inc(HALO), totaling $418,530.00. This investment constitutes 1.67% of their stock portfolio, and RYDEX SERIES FUNDS now holds 0.01% of the outstanding Halozyme Therapeutics Inc(HALO) stock.
The initial trade took place in 2021Q4. And since then S&P MidCap 400 Pure Growth Fund has made 4 purchases of HALO, at an average price of $43.51, for a total of 42,502.00 shares. In addition, there have been 6 sales at an average price of $43.69 for 35,943.00 shares. Based on historical transaction data and HALO's current price of $56.45, S&P MidCap 400 Pure Growth Fund's estimated gain on his HALO holdings is $91,208.42, reflecting a 4.93% gain to date.
S&P MidCap 400 Pure Growth Fund HALO ($56.45) Holding Chart
S&P MidCap 400 Pure Growth Fund HALO ($56.45) Quarterly Buys and Sells
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Avrg. Price |
|---|---|---|---|---|
| Shares Bought | 0 | Average Price $-/Share | ||
| Shares Sold | 0 | Average Price $-/Share | ||
| Current Price $0.00 | Total Estimated Gain 0 % | |||
Top Ranked Articles
- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
